Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Gene | FANCA |
Variant | L784Ffs*10 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | FANCA L784Ffs*10 indicates a shift in the reading frame starting at amino acid 784 and terminating 10 residues downstream causing a premature truncation of the 1455 amino acid Fanca protein (UniProt.org). L784Ffs*10 has not been characterized, however, due to the effects of other truncation mutations downstream of L784 (PMID: 33172906), is predicted to lead to a loss of Fanca protein function. |
Associated Drug Resistance | |
Category Variants Paths |
FANCA mutant FANCA inact mut FANCA L784Ffs*10 |
Transcript | NM_000135.4 |
gDNA | chr16:g.89769989_89769990insG |
cDNA | c.2351_2352insC |
Protein | p.L784Ffs*10 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000135.4 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
XM_005256294.4 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
XM_011522945.2 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
NM_001286167.3 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
NM_001286167.2 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
NM_000135.3 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
XM_017023044.2 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
XM_017023045.1 | chr16:g.89769989_89769990insG | c.2351_2352insC | p.L784Ffs*10 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|